Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human-derived mesenchymal stem cell conditioned medium for respiratory distress in lung disease
jRCT1051240234Recruiting
- Sponsor
- Kawagoe Chuo Clinic
- Start
- Sep 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ACT-20-CM in pulmonary diseases and respiratory distress syndrome (RDS), sponsored by Kawagoe Chuo Clinic. Primary endpoint: Improvement of subjective symptoms. Started Sep 2023; status: recruiting.
02
Drugs
ACT-20-CM
03
Conditions
pulmonary diseasesrespiratory distress syndrome (RDS)
Beyond the preview
Go deeper on jRCT1051240234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051240234.